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Abstract: Drug discovery has moved toward more rational strategies based on our increasing
understanding of the fundamental principles of protein–ligand interactions. Structure-
(SBDD) and ligand-based drug design (LBDD) approaches bring together the most powerful
concepts in modern chemistry and biology, linking medicinal chemistry with structural biol-
ogy. The definition and assessment of both chemical and biological space have revitalized the
importance of exploring the intrinsic complementary nature of experimental and computa-
tional methods in drug design. Major challenges in this field include the identification of
promising hits and the development of high-quality leads for further development into clini-
cal candidates. It becomes particularly important in the case of neglected tropical diseases
(NTDs) that affect disproportionately poor people living in rural and remote regions world-
wide, and for which there is an insufficient number of new chemical entities being evaluated
owing to the lack of innovation and R&D investment by the pharmaceutical industry. This
perspective paper outlines the utility and applications of SBDD and LBDD approaches for
the identification and design of new small-molecule agents for NTDs.
Keywords: biological activity; computer-aided molecular design; drug discovery; enzymes;
enzyme inhibitors; ligand-based drug design; medicinal chemistry; neglected tropical dis-
eases; structure-based drug design; structure–activity relationships. 
INTRODUCTION
Neglected tropical diseases (NTDs) place a heavy burden on society in terms of long-term disability,
illness, and death, with severe social and economic consequences for millions of people worldwide
[1–3]. Despite their high prevalence, in most cases the treatment for NTDs is inadequate and incredibly
limited (it is usually characterized by a low efficacy and considerable toxicity of the existing drugs),
leading to an urgent and immediate demand for new drugs. However, in addition to the traditional chal-
lenges involved in the complex process of drug discovery and development, it is widely recognized that
there is an innovation gap and a lack of pharmaceutical R&D investment in the area of NTDs [4–6].
Drug discovery is driven by innovation employing a combination of experimental and computa-
tional methods. In this context, the integration of modern drug discovery approaches allowing hit iden-
tification and lead optimization, as well as the discovery of innovative new chemical entities, are major
challenges in this field [7–11]. The use of structure- (SBDD) and ligand-based drug design (LBDD)
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methods is especially attractive for drug discovery for NTDs [3,12]. Over the past years, SBDD and
LBDD have evolved and transformed these approaches in tools of large impact in modern drug design.
In general, one of the most important issues that must be addressed during the selection of the appro-
priate approach is the evaluation of the nature and level of the molecular information available. For
instance, LBDD approaches are powerful methods based on only small-molecule information using a
series of known active and inactive compounds, whereas SBDD approaches incorporate information
from the target receptor [13,14]. It is worth noting that these knowledge-driven approaches can be
explored in combination, creating new opportunities for innovation in medicinal chemistry in order to
maximize the accomplishment of drug discovery projects. Recent successful examples highlight the
diversity of SBDD and LBDD strategies, assembling the most powerful concepts in chemistry and biol-
ogy, with particular emphasis on the field of NTDs [2,7–9]. 
This paper outlines the fundamental principles and state of the art in the integration of SBDD and
LBDD strategies for the discovery of innovative chemotherapy agents for a variety of NTDs, high-
lighting advances, limitations, and future perspectives in medicinal chemistry.
SBDD AND LBDD APPROACHES FOR NEGLECTED TROPICAL DISEASES
A useful strategy for the design of new active compounds against NTDs relies on the investigation of
unique biochemical pathways and proteins of the pathogens. In line with this, trypanothione reductase
(TR), an essential enzyme of the thiol metabolism in trypanosomatids, has been explored as a molecu-
lar target for the development of new chemotherapy agents [15]. TR is a key enzyme of the parasite
redox system involved in the protection against oxidative damage and supply of reducing equivalents
for DNA synthesis [14,15]. SBDD approaches applied for the development of TR inhibitors have
proven challenging owing to the difficulty of determining the binding modes of several ligands.
Nonetheless, molecular modeling strategies have been employed to provide useful structural informa-
tion for inhibitor drug design [16–18]. An important example is the design of a series of diaryl sulfide-
based derivatives as new TR inhibitors [19]. In this work, molecular docking strategies were employed
for the previously reported lead compound BTCP (Ki = 1 μM) [18], suggesting the binding of the lig-
and to the hydrophobic Z-site of the TR enzyme (Fig. 1A). Exploring the integration of SBDD (e.g.,
molecular docking) and LBDD (e.g., energy minimization and conformational analysis) approaches, a
diaryl sulfide analog (TR inhibition = 36 %, at 100 μM) containing a central imidazole moiety was pre-
dicted to simultaneously bind to the mepacrine binding site and the hydrophobic patch of the TR cat-
alytic cavity (Fig. 1B). According to the model, the presence of bulky substituents on the piperazine
moiety could positively influence the inhibitory activity of new derivatives through the occupation of
the hydrophobic Z-site. In addition, a combination of the imidazole-based diaryl sulfide derivative with
BTCP would optimize the interactions with the TR binding pocket, and therefore yield a compound
with higher binding affinity (Fig. 1C). Following this, 48 triazole- and imidazole-based diaryl sulfide
derivatives were synthesized and evaluated against TR. The results showed that seven derivatives exhib-
ited significant TR inhibition (TR inhibition > 50 %, at 40 μM). As expected, the most promising
inhibitor (1) (Ki = 0.51 μM, Fig. 1D) showed a competitive type of inhibition with respect to the sub-
strate trypanothione disulfide (TS2), and at the concentration of 20 μM, did not affect the activity of the
human homolog glutathione reductase (GR, 40 % sequence identity to TR) [19]. Additionally, com-
pound 1 exhibited in vitro activity in the sub- to low micromolar range against a panel of protozoan par-
asites, including Trypanosoma cruzi, Trypanosoma brucei rhodesiense, Leishmania donovani, and
Plasmodium falciparum, with selectivity index (SI) between 4 and 165 (SI = IC50 L6 cells/IC50 para-
site).
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Detailed structural information of several parasite enzymes is available in public databases such
as the Protein Data Bank (PDB) [20]. The combination of structural data and chemogenomics
approaches is useful for the evaluation of the biological relevance and “druggability” profile (i.e., the
likelihood that a target is amenable to functional modulation through interaction with a therapeutic
agent) of these target proteins [21–23]. The strategy highlights attractive molecular targets for SBDD,
providing new opportunities for hit identification and lead discovery [12]. In this context, organisms
such as T. brucei, T. cruzi, and P. falciparum have several key enzymes implicated in pathogenesis and
host cell invasion, including a number of closely related proteases [24,25]. In P. falciparum, plas-
mepsins (aspartic protesases) and falcipains (cysteine proteases) catalyze the degradation of host hemo-
globin to provide nutrients for exponential growth and maturation of the pathogen [26]. Indeed, the cys-
teine proteases falcipain-2, -2', and -3 play an important role in Plasmodium development, and their
inhibition may suppress parasite growth [27]. Similarly, in trypanosomatids, the cysteine proteases
rhodesain (cathepsin L-like) and cathepsin B (TbCatB, cathepsin B-like) from T. brucei and cruzain
(cathepsin L-like) from T. cruzi play a pivotal role during the infection of host cells, replication, and
metabolism [24]. Overall, this class of enzymes is among the most investigated targets for the develop-
ment of new antitrypanosomal agents. The protozoan enzymes falcipain, rhodesain, TbCatB, and
cruzain share common features of the cysteine proteases family, such as the classical papain fold con-
sisting of two distinct domains (Fig. 2A). The superimposition of the structures reveals a high degree
of structural similarity (Cα RMSD: 0.5–2.5 Å), with the highest conservation observed in the catalytic
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Fig. 1 Predicted binding mode of BCTP (A), imidazole-based diaryl sulfide derivative (B) and conjugated
compound (1) (C). Biological data for compound (1) (D) (Tr = trypanothione reductase enzyme; Tbr = T. brucei
rhodesiense; Tc = T. cruzi; Ld = L. donovani; Pf = P. falciparum; L6 = rat myoblast L6 cells line strains to assess
cytotoxicity).
domain (Cα RMSD: 0.3–0.4 Å). The catalytic dyad (cruzain = Cys25 and His 162; rhodesain = Cys25
and His 162; TbcatB = Cys 122 and His 282; falcipain = Cys 42 and His 174) is embedded in a chan-
nel-like junction between the two domains with highly conserved amino acids (Fig. 2B). Therefore, cys-
teine protease inhibitors could be useful lead candidates for these related parasitic infections. 
In general, cysteine protease inhibitors exhibit an electrophilic functional group to form an irre-
versible or reversible covalent thioimidate intermediate with the catalytic cysteine [28]. In line with this,
a series of triazine nitrile derivatives was designed as potent inhibitors of rhodesain and falcipain-2 [29].
Molecular modeling studies provided useful insights into the binding mode and structure–activity rela-
tionship (SAR) of this series of inhibitors. The results highlighted the importance of the diamino-sub-
stituted triazine core structure to direct the orientation of substituents in the S1, S2, and S3 binding
pockets. The predicted binding mode of the lead compound (2) suggests key features, including (i) a
morpholine group as substituent to occupy the S1 pocket, (ii) a 4-(n-propyl)cyclohexyl substituent to
occupy the hydrophobic S2 pocket, and (iii) a 1,3-benzodioxol-5-yl moiety to interact with the S3
pocket (Fig. 3A). Thus, a series of 17 triazine nitrile derivatives was synthesized and evaluated against
rhodesain and falcipain-2. The most promising competitive inhibitor (3) showed inhibitory potency in
the low nanomolar range (Fig. 3B). Compound (3) showed no inhibition against a panel of proteases,
including human cathepsin B, viral cysteine proteases as well as α-chymotrypsin (serine protease). In
R. V. C. GUIDO et al.
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Fig. 2 (A) Papain cysteine protease family representative fold consisting of two distinct domains. (B)
Superimposition of the X-ray crystal structures of rhodesain (green, PDB ID: 2P86), cruzain (cyan, PDB ID: 3I06)
TbcatB (magenta, PDB ID: 3HHI) and falcipain-2 (yellow, PDB ID: 3BPF). (C) Superimposition of the key amino
acid residues in the catalytic site of rhodesain (green), cruzain (cyan), TbcatB (magenta), and falcipain-2 (yellow).
addition, compound 3 exhibited moderate in vitro growth inhibitory activity against T. brucei rhode-
siense (IC50 = 30.1 μM) and P. falciparum (IC50 = 2.9 μM).
In the past decade, the development of a number of irreversible inhibitors of cruzain has demon-
strated the usefulness of this approach in inhibitor drug design for infectious diseases [30]. In order to
identify new reversible covalent inhibitors of cruzain, high-throughput screening (HTS) was conducted
employing approximately 200000 compounds from the NIH Molecular Library [31]. The identification
of reversible inhibitors offers the potential of fewer off-target binding and side-effects, which are fre-
quently associated with irreversible enzyme inhibitors. The screening hits prioritized belong to several
classes of molecular scaffolds. The counter screening process on these promising chemotypes con-
firmed the triazine derivative (4) as an inhibitor of cruzain, with a Ki value of 180 nM (Fig. 4A). Further
kinetic investigations revealed a reversible and competitive type of inhibition. Hit-to-lead and SAR
studies indicated that hydrophobic substituents at the 4-amino group, electron-withdrawing substituents
at the 6-phenylamino group, as well as structural rigidity were favorable for cruzain inhibition. The lat-
ter observation was accomplished by the generation of purine-derived nitriles as new lead compounds.
The incorporation of these features led to compound 5, which exhibited potent inhibition of the target
enzyme with an IC50 of 0.2 nM (Fig. 4B). These results encouraged the development of X-ray crystal-
lography studies, and the high-resolution complex obtained (1.1 Å) not only revealed important molec-
ular aspects responsible for the biological activity of this series of inhibitors, but also indicated relevant
structural elements involved in the covalent, reversible inhibition mechanism (Fig. 4C). For instance,
the formally linear nitrile became a planar imino-moiety as the covalent adduct with the catalytic Cys25
is formed. Additionally, the purine moiety binds between the S1 and S2 pockets, the aromatic ring at
© 2012, IUPAC Pure Appl. Chem., Vol. 84, No. 9, pp. 1857–1866, 2012
Structure- and ligand-based drug design 1861
Fig. 3 Molecular structure, biological data, and predicted binding mode of the lead compound (2) (A), and the most
promising cysteine protease inhibitor (3) (B) into the binding pocket of rhodesain (green) and falcipain-2 (yellow).
Hydrogen bonds are depicted as blue dashed lines (Tb = Trypanosoma brucei rhodesiense; Pf = Plasmodium
falciparum).
the N6-position extends into the hydrophobic S2 pocket and the N9-ethyl substituent is solvent-exposed,
suggesting an attractive position for the improvement of pharmacokinetic properties (Fig. 4C).
Considering the structural similarities of the parasite’s cysteine proteases, compound 5 was also evalu-
ated against the T. brucei homologs rhodesain and TbcatB, showing inhibitory potency in the low
 namolar (IC50 = 60 nM) and micromolar (IC50 = 6 μM) ranges, respectively (Fig. 4B). In spite of its
cruzain inhibitory activity, compound 5 was not active against whole cell cultures of T. cruzi.
Conversely, promising activity was detected against T. brucei (MIC50 = 25 μM, Fig. 4B). The selectiv-
ity profile of 5 was evaluated over a panel of 71 proteases, including 22 cysteine proteases, 4 aspartyl
proteases, 26 serine proteases, 5 peptidases, and 14 matrix metalloproteinases. Compound 5 was active
only against closely related cysteine proteases, however, with significant SI values ranging from
80 (cathepsin-S) to 50.000 (cathepsin-B).
The integration of SBDD and LBDD approaches has found its way into drug discovery programs
for NTDs [32–38]. Good examples can be seen in the use of 3D QSAR methods, such as comparative
molecular field analysis (CoMFA) [39,40] and comparative molecular similarity index analysis
(CoMSIA) [41,42]. These QSAR methods rely on the relative spatial orientation of series of ligands
(structural alignment) into the binding site of the target protein. The 3D structure of the protein along
with an appropriate docking tool is used to guide the molecular alignment of the dataset for the QSAR
analysis. The quality of the conformations of the compounds (superposition of the bioactive molecules)
is of fundamental importance for all subsequent procedures. The combined approach, which incorpo-
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Fig. 4 Molecular structure and biological data of the HTS hit (4) (A), and of the developed compound (5) (B)
(Tb = Trypanosoma brucei). (C) Experimental binding mode of the compound (5) within the cruzain catalytic site
(PDB ID: 3I06). Hydrogen bonds are depicted as blue dashed lines, and crystallographic water molecules as red
spheres.
rates components at the micro- and macromolecular level, allows the generation of a target-specific
scoring method considering the available chemical and biological data (Fig. 5). 
A number of successful examples of the application of this drug design strategy have been
reported in the area of NTDs [43–46]. For instance, CoMFA and CoMSIA methods were employed to
investigate a large series of adenosine analogs, exploring structural differences between the human and
trypanosomatid glyceraldehyde-3-phosphate dehydrogenase (GAPDH) enzymes [47]. The integration
of molecular docking and 3D QSAR was a useful strategy for the generation of highly predictive mod-
els. In addition, the CoMFA and CoMSIA contour maps, representing the effects of the steric, electro-
static, hydrophobic, and hydrogen-bond donor and acceptor molecular fields, allowed the identification
of key chemical and structural features responsible for selectivity and biological potency [47].
Similarly, molecular modeling studies were carried out in order to identify the preferred binding mode
of a series of thiosemicarbazone derivatives as covalent reversible inhibitors of cruzain [48]. Docking
investigations led to the identification of the essential structural requirements for the molecular align-
ment, and robust CoMFA and CoMSIA models were developed on the basis of the predicted bioactive
conformations. The models possessed high internal and external consistency, showing substantial pre-
dictive power. Additionally, detailed analysis of the CoMFA electrostatic maps provided structural
insights into the reversible covalent mechanism of inhibition of this class of compounds. According to
the model, key hydrogen bond interactions may play an important role in the backward reaction [48].
Several steps of the drug discovery process (e.g., hit identification, lead optimization, NCE dis-
covery) can be improved in a rational way with the application of SBDD and LBDD methods [2,7–9].
In this context, virtual screening has become a highly valued and widely used tool for the identification
of hits and lead compounds for a variety of therapeutically important target proteins [2,49–52]. An
example can be seen in the medicinal chemistry approach employed for the discovery of new inhibitors
of Schistosoma mansoni purine nucleoside phosphorylase (SmPNP), which outlines a successful sce-
nario for the integration of computational and experimental methods. PNP is a key enzyme involved in
the purine salvage pathway of S. mansoni, one of the causative agents of human schistosomiasis
[53,54]. In this work, a structure-based pharmacophore model was employed for the virtual screening
of a huge library of compounds, leading to the identification of three thioxothiazolidinones derivatives
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Fig. 5 Integration of SBDD and LBDD with 3D QSAR methods.
with substantial in vitro inhibitory activity against SmPNP (Fig. 6A) [55]. Convenient synthesis, bio-
chemical evaluation, and SAR studies led to the successful development of a set of thioxothiazolidinone
derivatives harboring a novel chemical scaffold as new competitive inhibitors of SmPNP in the low
micromolar range. The most potent inhibitors (6–8) represent new lead compounds for further devel-
opment for the therapy of schistosomiasis (Fig. 6B).
CONCLUSIONS
In the past years, SBDD and LBDD have been successfully applied in the identification and develop-
ment of several new classes of inhibitors of key enzymes for NTDs. The integration of these approaches
is a useful and valuable tool for the prioritization of compounds for further investigation involving com-
putational and experimental methods. In spite of the intrinsic technical limitations, there are many
examples demonstrating the cost effectiveness and reliability of these methods in the generation of lead
compounds. Noteworthy, the structural diversity of the compounds identified considerably differs from
the drugs currently available, thereby providing good starting points for lead optimization, as well as
for the discovery of high-quality new chemical entities. Although there are many fundamental aspects
to be further explored in the integration of SBDD and LBDD, these approaches will continue to evolve
and have considerable impact in the development of new drug candidates for parasitic diseases, and it
is likely to remain as such for the foreseeable future.
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Fig. 6 (A) Predicted binding mode of the lead compounds (6) (beige), (7) (yellow), and (8) (light blue) overlaid on
the four-point structure-based pharmacophore model employed in the virtual screening of a large database of
commercially available compounds. The hydrophobic favorable region within the SmPNP binding site is indicated
as an orange sphere; donor and acceptor favorable regions are depicted as blue and magenta spheres, respectively.
(B) Molecular structure and biochemical data of the reversible and competitive SmPNP inhibitors.
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